Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict nerve damage from common chemo drug

NCT ID NCT06490159

Recruiting now Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study investigates whether a blood test can predict which stomach cancer patients will develop nerve damage (peripheral neuropathy) from the chemotherapy drug paclitaxel. Paclitaxel is a standard second-line treatment for advanced gastric cancer, but nerve damage is a common and troublesome side effect. Researchers aim to develop a liquid biopsy assay to identify high-risk patients before treatment, enabling more personalized and safer chemotherapy choices. The study enrolls 150 adults with unresectable or recurrent gastric cancer who have progressed on first-line therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Paclitaxel
What this could lead to
If successful, this could lead to a simple blood test that identifies patients at high risk for nerve damage before starting paclitaxel, allowing doctors to choose safer treatments.
What could go wrong
This is an early-stage observational study focused on prediction, not treatment. The blood test may not prove accurate enough for clinical use, and it does not prevent or cure neuropathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY GASTRIC CANCER PACLITAXEL RAMUCIRUMAB

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kawasaki Medical University

    RECRUITING

    Kurashiki, Okayama-ken, 7010192, Japan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.